Dario Alvarez plans a future as a pediatrician to serve underrepresented communities.Continue reading
Category Archives: AZBio News
Helios Scholars at TGen prepares students for success
One intern seeks physician-scientist career after participating in real-life biomedical research at TGenContinue reading
Aqualung Therapeutics Corporation Receives $1.7 Million National Institute of Health (NIH) Fastrack Award
AQUALUNG THERAPEUTICS CORPORATION receives a $1.7 MILLION National Institutes of Health (NIH) Fastrack award to develop a novel immune-based therapeutic anitibody for critically ill patients with acute lung injury.
Arizona at BIO 2019
The BIO International Convention has concluded. Hosted by the Biotechnology Innovation Organization (BIO), this year’s Convention drew 17,307 attendees from 49 states, the District of Columbia, Puerto Rico and 65 countries to Philadelphia and its burgeoning biotech community.Continue reading
Plans for Oro Valley Innovation Lab or OVIL Progresss
A planned Oro Valley biotech incubator has secured additional funding, with Pima County signing on to allocate up to $60,000 for development.
The biotech incubator, Oro Valley Innovation Labs, is intended to add to the growing high-tech industry in Pima County by providing space for nascent businesses to conduct research and product development, with a focus on medical diagnostics.
Read more at Tucson.com: https://tucson.com/business/planned-oro-valley-biotech-incubator-secures-additional-funding/article_556b35e7-6c14-59d2-a0eb-9ef9bc4e0efc.html
OncoMyx Therapeutics Completes $25 Million Series A Financing
PHOENIX, AZ – June 5, 2019 – OncoMyx Therapeutics, a privately-held oncolytic immunotherapy company founded on the myxoma virus (MYXV) platform from Arizona State University (ASU), announced today the completion of a $25 million series A financing led by Boehringer Ingelheim Venture Fund (BIVF), Delos Capital, and Xeraya Capital with participation from Korea Investment Partners (KIP), City Hill Ventures, and Madison Partners. OncoMyx plans to use the proceeds to advance development of its lead oncolytic virus (OV) therapeutic program for the treatment of various cancers.Continue reading
Roche launches first in vitro diagnostic IHC test to detect ROS1 protein in cancers
- Roche’s VENTANA ROS1 (SP384) Rabbit Monoclonal Primary Antibody is the first and only in vitro diagnostic ROS1 immunohistochemistry assay on the market
- The biomarker may provide a cost-effective and efficient means to initially identify elevated ROS1 protein expression in cancer
- ROS1-positive cancer cases, which are predominantly found in younger non-smokers,1 account for 1-2 percent of all non-small cell lung cancer (NSCLC) cases